This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: Hi-Yo Silver!

Click here for an archive of Cramer's "Mad Money" recaps.


Drug Paraphernalia

Want a new drug? Jim Cramer had two for his "Mad Money" TV show viewers on Monday.

He said that ACP-103 and ACP-104, which are being developed by Acadia Pharmaceuticals (ACAD), could make you some mad money.

The company makes antipsychotic drugs, said Cramer, and he believes that Acadia could change the way we treat schizophrenia and bipolar disorder.

Interim results from phase II trials for ACP-103 are coming out soon as a treatment for Parkinson's, he said, adding that more results are due out later in the year.

Plus, Cramer said that ACP-104 has phase II results coming out later this year for its antipsychotic that he said is basically a better version of the widely used antipsychotic Clozapine.

Clozapine has some very bad side effects, he said; and it's off patent, so no one can make any money from it.

If all of these tests fail, Cramer said the stock could go down three points or so from its current level above $10. But if it nails the trials, he believes the stock could run to $50.

Sepracor (SEPR), the maker of Lunesta, has already invested in Acadia, and Cramer believes more investment could come soon.

A caller wanted to know about American Shared Hospital Services (AMS), which is also working on a Parkinson's treatment.

Cramer said the company is interesting and profitable, but it has a market cap of only $31 million. He likes to look at companies with a minimum market cap of $200 million to $250 million.

That's because if he praised a company as small as American Shared Hospital Services on the show, he fears that there would not be enough supply to meet demand, and people would get hurt.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs